Terumo : to Implement New Executive Officers' Management System

February 9, 2022

TOKYO, JAPAN - February 9, 2022 - Terumo Corporation (TSE: 4543) today announced that in conjunction with the new 5-Year Growth Strategy with a 10-Year Vision (GS26) starting next fiscal year, the company will implement a new Executive Officers' Management System effective from April 1, 2022 onwards. This new management system will redefine the responsibilities of both the Executive Officers representing the entire Terumo Group and the Executive Officers representing Terumo Corporation.

The current Executive Officers' Management System was implemented in 2002 with its structure built mainly around the headquarter in Japan . Since then, Terumo has rapidly expanded its business globally. The new Executive Officers' Management System will play a part to enhance Terumo Group's competitiveness on a global level and to achieve our visions defined in GS26.

The changes implemented in the new Executive Officers' Management System is as follows.

1. Establishment of Group Executive Officer (GEO)

Group Executive Officers will be responsible to set management directions and to discuss Terumo Group management strategies beyond business divisions and regions.

The GEO will be structured around Directors and Executive Officers such as the Chairman of the Board, the President and CEO, Company Presidents, Corporate Function Executives, CEOs of Major Business Subsidiaries, and Regional Representatives.

Furthermore, among the GEO structure, the Group Managing Executive Officer (GMEO) will take part in the Executive Management Meeting (EMM) as a core member to execute management strategies for the Terumo Group. By definition, the GMEOs must be a Managing Executive Officer/Senior Managing Executive Officer or higher.

2.Redefinition of Executive Officer (EO)

Executive Officers are those who are not part of GEO and is responsible for making decisions for their Company or Function.

In addition, the new Executive Officers' Management System clarifies each members' job description based on their position and responsibility. Appointment of each Executive Officer will be based on this clarified criteria and process. For Terumo Corporation in Japan, positions above managers will also implement the same methodology and approach.

With the new Executive Officers' Management System taking place, Terumo will strive towards realizing GS26 and further drive global growth.

Appendix: Executive Officers (As of April 1, 2022)

■Group Executive Officer: GEO

Group Managing Executive Officer: GMEO

[Chairman of the Board]

Toshiaki Takagi

[President and CEO]　

Shinjiro Sato

[Company President]

Group Senior Managing Executive Officer	Hikaru Samejima	Medical Care Solutions Company
Group Senior Managing Executive Officer	Toshihiko Osada	Cardiac and Vascular Company
Group Managing Executive Officer	Antoinette Gawin	Blood and Cell Technologies Company

[Corporate Functions]

Group Senior Managing Executive Officer	Shoji Hatano
Group Managing Executive Officer	Kyo Nishikawa	Chief Human Resources Officer (CHRO)
Group Managing Executive Officer	Kazunori Hirose	Chief Manufacturing Officer (CMO)
Group Managing Executive Officer	Fumihisa Hirose	General Manager, Strategic Planning Dept. and Chief Technology Officer (CTO)

Group Executive Officer: GEO

[CEOs of Major Business Subsidiaries]

Group Executive Officer	James Rushworth	President and CEO, Terumo Medical Corp.
Group Executive Officer	Robert DeRyke	President and CEO, Terumo Cardiovascular Systems Corp.
Group Executive Officer	Carsten Schroeder	President and CEO, MicroVention, Inc.
Group Executive Officer	Erik Pomp	President and CEO, Terumo Aortic

[Regional Representative]

Group Executive Officer	Hiroshi Nagumo	Regional Representative, Americas
Group Executive Officer	Probir Das	Regional Representative, Asia Pacific and India
Group Executive Officer	Norimasa Kunimoto	Regional Representative, Europe, Middle East and Africa
Group Executive Officer	Masayuki Maruta	Regional Representative, China

[Corporate Functions]

Group Executive Officer

Naoki Muto

Chief Accounting and Financial Officer (CAFO)

■Executive Officer

[Company]

Senior Executive Officer	Tsuyoshi Tomita	Division President, Hospital Care Solution Division, Medical Care Solutions Company
Senior Executive Officer	Itaru Sakaguchi	Chief Operations Officer (COO), Interventional Systems Division, Cardiac and Vascular Company President, Terumo Yamaguchi Corp.
Executive Officer	Takeshi Kuroo	Senior Vice President, Surgical Business, Cardiac and Vascular Company General Manager, HeartSheet Business Dept., Cardiac and Vascular Company
Executive Officer	Hiroshi Yagi	General Manager, Ashitaka Factory, Interventional Systems Division, Cardiac and Vascular Company
Executive Officer	Noritsugu Fujita	Division President, Pharmaceutical Solution Division, Medical Care Solutions Company

[Corporate Functions]

Senior Executive Officer	Kazuhisa Senshu	Chief Clinical and Regulatory Affairs Officer (CRAO)
Executive Officer	Miho Mizuguchi	Chief Legal Officer (CLO)
Executive Officer	Tomoko Manabe	General Manager, Terumo Medical Pranex
Executive Officer	Keiji Takeda	General Manager, Human Resources Dept.
Executive Officer	Toshio Nakashima	Chief Quality Officer (CQO)
Executive Officer	Jin Nishizaki	General Manager, Japan Sales Dept.
Executive Officer	Hitoshi Hasegawa	Chief Information Officer (CIO)

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Media Contact

Corporate Communication Dept., Terumo Corporation

Contact us

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.

Print